专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06833256B1 Interferon tau mutants and methods for making them 失效
标题翻译：干扰素tau突变体及其制备方法
公开(公告)号：US06833256B1
公开(公告)日：2004-12-21
申请号：US09599413
申请日：2000-06-22
申请人： Carol H. Pontzer , Lynnette H. Shorts , Christina Dancz Clark
发明人： Carol H. Pontzer , Lynnette H. Shorts , Christina Dancz Clark
IPC分类号： C12P2104
CPC分类号： C07K14/555 , A61K38/00
摘要： The present invention is directed to the field of animal and human health, and more particularly to pharmacological uses of analogs or mutants of interferon-tau (IFN-&tgr;) that differ from native IFN-&tgr; because of substitutions of amino acids near the amino terminus of the IFN-&tgr; molecule that impart improved biological activity. The IFN-&tgr; mutants described in this disclosure have low toxicity, retain the same or slightly reduced antiviral activity compared with highly effective IFN-alpha, and have enhanced antiproliferative activity compared to native IFN-tau, making them useful in treating viral infections, cancer, and immune system diseases including autoimmune diseases. The present invention is also directed to a method for making novel recombinant proteins, especially interferons, interleukins, and cytokines, polypeptide hormones and other biopharmaceuticals that have improved biological activity over known proteins and/or lower toxicity and/or increased stability.
摘要翻译：本发明涉及动物和人类健康领域，更具体地涉及由于氨基末端附近的氨基酸取代而与天然IFN-τ不同的干扰素-τ（IFN-τ）的类似物或突变体的药理学用途的IFN-τ分子，其赋予改善的生物活性。在本公开中描述的IFN-τ突变体具有低毒性，与高效IFN-α相比保持相同或略微降低的抗病毒活性，并且与天然IFN-τ相比具有增强的抗增殖活性，使其可用于治疗病毒感染，癌症和免疫系统疾病，包括自身免疫性疾病。本发明还涉及一种制备新型重组蛋白质，特别是干扰素，白细胞介素和细胞因子，多肽激素和其它生物活性比已知蛋白质改善和/或降低毒性和/或增加的稳定性的生物药物的方法。

IPRDB

热门服务

关于我们

友情链接

联系方式